Wart war: vitamin d injection takes on acyclovir in new trial
NCT ID NCT07196670
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will test whether injecting vitamin D or acyclovir directly into plantar warts is more effective. Sixty adults with plantar warts will be randomly assigned to one of the two treatments, receiving up to four injections three weeks apart. After treatment, patients will be followed for one month to check for wart clearance and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vitamin D3 or acyclovir injected into the wart
What this could lead to
If one treatment works better, it could offer a simple, low-cost option for stubborn plantar warts.
What could go wrong
This is a small, early-phase trial with only 60 people and a short follow-up. Results may not apply to everyone, and warts may come back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLANTAR WARTS TREATMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.